Filing Flows › Akebia Therapeutics (AKBA) › Q1 2025
Akebia Therapeutics (AKBA) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Akebia Therapeutics (AKBA) reported revenue of $57.3M for the first quarter 2025 (Q1 2025), +76% from a year earlier and +23% from the quarter before. Operating margin was 23.6%, net earnings $6.1M (10.7% of revenue).
Akebia Therapeutics, Q1 2025: revenue $57.3M (+76% year over year), operating margin 23.6%, net earnings $6.1M, operating cash flow −$13.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $57.3M | +23% | +76% |
| Operating profit | $13.5M | — | — |
| Net earnings | $6.1M | — | — |
| Operating cash flow | −$13.6M | — | — |
What changed
Revenue was $57.3M in Q1 2025, up 76% year over year and up 23% from the previous quarter. Auryxia was the largest line at 76% of revenue. Auryxia added $12.7M year over year (up 41%), 52% of the total change. License, collaboration and other revenue declined 3%.
Operating profit was $13.5M, a 23.6% margin (up 69.4 points year over year). Total costs fell 8% while revenue rose 76%. Net earnings were $6.1M. The effective tax rate was 0.0%.
Operating cash flow was −$13.6M. Non-cash charges added back $314K of depreciation and amortization and $2.2M of share-based compensation. Working capital and other items used $22.2M. Capital expenditures of $18K exceeded it, leaving free cash flow of −$13.6M.
Questions
What was Akebia Therapeutics' revenue in the first quarter 2025?
Akebia Therapeutics (AKBA) reported revenue of $57.3M for the first quarter 2025 (Q1 2025), +76% from a year earlier and +23% from the quarter before.
Was Akebia Therapeutics profitable in the first quarter 2025?
Operating profit was $13.5M (23.6% of revenue) and net earnings $6.1M.